Not legal adviceThis page summarizes public FDA documents for readers who want to understand the status of a product they have been offered or prescribed. It is not legal or medical advice, and it does not recommend any source of tirzepatide. FDA statements: “Compounded drugs are not approved by FDA.”[1]
Timeline
Tirzepatide went on the FDA shortage list in December 2022, came off it in 2024, and compounders lost their grace periods in early 2025.[2][1]
| Date | What happened |
|---|---|
| Dec 15, 2022 | Tirzepatide injection added to the FDA drug shortage list.[2] |
| Oct 2, 2024 | FDA declares the shortage resolved.[1] |
| Dec 19, 2024 | After re-evaluation, a declaratory order: “FDA determines that the tirzepatide injection product shortage is resolved.”[2] |
| Feb 18, 2025 | End of the period in which FDA said it would not act against 503A pharmacies and physicians compounding tirzepatide.[1] |
| Mar 19, 2025 | End of the same period for 503B outsourcing facilities.[1] |
| Jan 7, 2026 | FDA approves Lilly's own multi-dose vial (four doses per vial) for Zepbound and Mounjaro.[8] |
| Apr 30, 2026 | FDA proposes excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list, saying it “did not identify a clinical need” for outsourcing facilities to compound them from bulk substances. Comments closed July 30, 2026; no final decision found as of November 13, 2026.[4] |
What is compounded tirzepatide?
Compounded tirzepatide is a version made by a compounding pharmacy or outsourcing facility instead of the manufacturer, without FDA approval.[1] How it compares with the approved product is on compounded tirzepatide vs Zepbound, and dose arithmetic on compounded tirzepatide dosage.
- Section 503A covers state-licensed pharmacies and physicians. Section 503B covers outsourcing facilities.[1]
- Once a shortage ends, the FDA “generally considers the drug to be commercially available,” and both pathways restrict making drugs that are “essentially copies” of an approved product.[1]
- As of April 2026, the FDA noted that tirzepatide does “not currently appear on the 503B bulks list or on FDA's drug shortage list.”[1]
What the FDA has said about safety
The FDA says compounded tirzepatide is not reviewed for safety, effectiveness or quality, and it has logged more than 730 adverse-event reports.[3]
- Unapproved versions “do not undergo FDA's review for safety, effectiveness and quality before they are marketed.”[3]
- The FDA has received “more than 730 reports of adverse events associated with compounded tirzepatide” through May 31, 2026.[3]
- It has found fraudulent compounded products whose labels name pharmacies that do not exist, and it has warned firms selling tirzepatide labeled “for research purposes” or “not for human consumption”.[3]
- With compounded semaglutide, the FDA documented dosing errors caused by confusion between mL, mg and “units” in multi-dose vials.[5]
Recent warning letters
In 2026 the FDA sent warning letters over misbranding, false “FDA approved” claims and compounding from a substance not on the 503B bulks list; four examples follow.
| Date | Recipient | Issue the FDA described |
|---|---|---|
| Feb 20, 2026 | BluefitMD | Product labels presented the website business as if it were the compounder; misbranding.[9] |
| Apr 7, 2026 | ProRx LLC (503B) | “tirzepatide does not appear on the 503B bulks list”; its 27 mg/3 mL multi-dose vials had been recalled for lack of sterility assurance.[10] |
| Jun 8, 2026 | Altru Telehealth | Claimed its compounding pharmacies were “FDA approved”. The FDA: “Compounded drug products are not FDA-approved.”[11] |
| Oct 30, 2026 | RonanRx | Misbranding; FDA records showed no drug listing for the active ingredient source the firm named.[12] |
Approved tirzepatide, for comparison
Every FDA-approved tirzepatide product is a ready-to-use solution with one strength per pen or vial: single-dose pens and vials hold one dose in 0.5 mL, and multi-dose vials and KwikPens hold four doses of 0.6 mL.[6][7] None of them is a powder, and none needs bacteriostatic water.
Reading a compounded vial label: the math
If you have a vial and want to check the arithmetic your prescriber or pharmacist gave you, the key is whether the label states a total or a concentration:
- Total: "27 mg/3 mL" means 27 mg spread through 3 mL, which is 27 ÷ 3 = 9 mg/mL.
- Concentration: "10 mg/mL" means every mL holds 10 mg, whatever the vial size.
Then units on a U-100 syringe = dose ÷ mg/mL × 100. At 9 mg/mL, the label doses would be:
| Dose | mL | Units (U-100) |
|---|---|---|
| 2.5 mg | 0.278 | 27.8 |
| 5 mg | 0.556 | 55.6 |
| 7.5 mg | 0.833 | 83.3 |
| 10 mg | 1.111 | 111.1 |
| 12.5 mg | 1.389 | 138.9 |
| 15 mg | 1.667 | 166.7 |
Use the calculator for your own numbers, and confirm any measurement with the pharmacist who dispensed it. The FDA has reported fraudulent products whose labels name pharmacies that do not exist.[3]
Related
Two questions that often come up alongside compounding are answered on tirzepatide pills and microdosing tirzepatide.
- Bac water mathConcentration and units for powder vials
- Approved Zepbound vialsSingle-dose and multi-dose
- Units to mg chartEvery concentration in one table
Frequently asked questions
What is compounded tirzepatide?
Tirzepatide made by a compounding pharmacy or outsourcing facility rather than by Eli Lilly. It is not FDA-approved.[1]
Is compounded tirzepatide legal?
Compounded drugs are not FDA-approved. Since the shortage was declared resolved, the FDA has said it generally considers tirzepatide commercially available, and compounders may not make drugs that are essentially copies of it. The grace periods for compounders ended in February and March 2025.[1] Specific situations depend on federal and state law.
Is compounded tirzepatide the same as Zepbound?
Not in regulatory terms. Zepbound is FDA-approved and its quality is reviewed by the FDA; compounded versions are not.[3]
Is there an FDA-approved multi-dose tirzepatide vial?
Is "research use only" tirzepatide approved?
No. The FDA has warned firms selling unapproved tirzepatide labeled "for research purposes" or "not for human consumption".[3]
Sources
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Declaratory order: resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound)
- FDA's concerns with unapproved GLP-1 drugs used for weight loss
- FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
- Zepbound (tirzepatide) injection: prescribing information, Medication Guide and Instructions for Use
- Mounjaro (tirzepatide) injection: prescribing information and Instructions for Use
- Zepbound supplement approval letter S-037 (multi-dose vial)
- Warning letter: BluefitMD
- Warning letter: ProRx LLC
- Warning letter: Altru Telehealth
- Warning letter: RonanRx